Metabolic Capacity Expansion And Peptide Outsourcing Shifts Will Face Headwinds Yet Ultimately Support Upside

AnalystLowTarget

Analyst Low Target compiles bearish analysts opinions to create narratives which represent one standard deviation below the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published

16 Dec 25

Updated

10 Jul 26

Views

Not Invested

Shared on 10 Jul 26

Fair value Decreased 11%

PPGN: Takeover Hopes Will Test Sustainability Of Recent Share Price Surge

PolyPeptide Group’s shares jump on takeover chatter, but some analysts now warn the stock may already be pricing in a best-case deal and leaving little room for disappointment. With one firm turning more cautious, the next headlines—and whether the business keeps delivering—could decide if sentiment holds or snaps back.

1 view

Fair Value vs Share Price

CHF 25.77

vs CHF 4470.7% overvalued

20.7%

Revenue growth

12.1%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on PolyPeptide Group

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Excellent balance sheet with reasonable growth potential.

Market capCHF 1.5b

PB4.4x

Estimated Growth13.7%

Dividend Yield0%

Full analysis

CEO & management

Juan Gonzalez

CEO

3.3yrs

CEO Tenure

Operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally.